TNF Blockers News and Research

RSS

Arthritis drug wins approval for use in children with Crohn's disease

The Food and Drug Administration in the U.S. has given approval for the drug Remicade for use in children with active Crohn's disease(CD), a chronic and debilitating condition.

21 May 2006

New rheumatoid arthritis drugs may put patients at risk of infections and cancer

Anti-TNF (tumor necrosis factor) therapies are a tried and tested type of medication used for treating rheumatoid arthritis and the drugs provide benefit to many of thousands of patients worldwide.

21 May 2006

Study shows strong association between treatment with TNF-blocking antibodies and development of serious infections

A new meta-analysis of many previous studies of TNF- (tumor necrosis factor) blocking antibodies for treatment of rheumatoid arthritis has confirmed a previously discovered increased risk for serious infection and has found that cancer also is a potential risk associated with the drugs.

17 May 2006

Etanercept and chemo might reduce fatigue in cancer patients

Researchers here have found evidence that combining a drug typically used to treat rheumatoid arthritis with chemotherapy might help reduce fatigue and muscle wasting that often afflicts cancer patients.

3 May 2006

MIT look at how cells make life-or-death decisions

The biological processes underlying diseases such as rheumatoid arthritis and cancer are fundamentally linked, and should be linked in how they are treated with drugs, a series of MIT studies indicates.

6 Apr 2006

New test for detecting small amounts of proteins in the blood

Researchers at the University of Pennsylvania School of Medicine have developed a paradigm-shifting method for detecting small amounts of proteins in the blood.

13 Mar 2006

Thalidomide, Lenalidomide show promise against Lou Gehrig's disease

New animal research suggests that two well-studied drugs, thalidomide and its derivative, lenalidomide, might extend the survival of patients with the neurological disorder amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

9 Mar 2006

FDA approves Rituxan (Rituximab)

Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.

1 Mar 2006

Link between rheumatoid arthritis and cancer examined

Rheumatoid arthritis is an inflammatory disease of the immune system and is thought to be linked to an increased risk of cancers of the lymphatic system.

28 Feb 2006

Study associates chronic, severe inflammation with increased lymphoma risk among RA patients

An inflammatory disease of the immune system, rheumatoid arthritis (RA) is associated with increased occurrence of lymphoma--or cancers of the lymphatic system, which plays an integral role in the body's ability to fight infection.

27 Feb 2006

Protein levels predict bone marrow transplant survival

Researchers say that protein levels can predict which bone marrow transplant patients are likely develop a deadly complication a week after the procedure and well before any symptoms occur.

19 Feb 2006

Protein level predicts who will develop graft vs. host disease after marrow transplant

Researchers could determine one week after a bone marrow transplant which patients were likely to develop a serious and deadly complication, making them candidates for preventive treatment before any symptoms occur.

17 Feb 2006

Anti-malarials most effective in lupus patients genetically at risk of high levels of TNF-alpha

Anti-malarial drugs are most effective in people with lupus who are genetically predisposed to high levels of tumour necrosis factor alpha and low levels of the cytokine IL-10.

16 Feb 2006

Evidence supports combination therapy for achieving remission of early rheumatoid arthritis

A chronic and potentially crippling inflammatory disorder, rheumatoid arthritis (RA) progressively wears away the cartilage and bone.

8 Jan 2006

New pathways linking liver disease to changes in the central nervous system

Liver disease is often associated with "sickness behaviors," such as malaise, listlessness, anorexia, difficulty concentrating, and fatigue. In cholestatic liver diseases (where bile production is impaired) such as primary biliary cirrhosis, fatigue occurs in up to 86 percent of patients.

5 Jan 2006

The role of genes in the development of non-Hodgkin's lymphomas

An international consortium of epidemilogists - including Dr. Alexandra Nieters and Professor Nikolaus Becker of the Clinical Epidemiology Division of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) - has conducted the first ever investigation of genetic factors in the development of non-Hodgkin’s lymphoma (NHL) in a study called InterLymph.

15 Dec 2005

Long-term benefits of initial combination therapy for rheumatoid arthritis

A progressive, inflammatory disease affecting the joints and organs, rheumatoid arthritis (RA) claims more than two million Americans, mostly women over age 40, among its victims.

30 Oct 2005

Remicade can improve psoriasis symptoms

An international team led by a dermatologist at The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve psoriasis symptoms.

From The University of Manchester 13 Oct 2005

Gut antibody could prove to be a promising drug target for Crohn's disease

A collaboration led by the Burnham Institute for Medical Research has found that an antibody which binds to an unusual sugar molecule residing in the gut halts the inflammation seen in Crohn's disease and other intestinal inflammations. The antibody could prove to be a promising drug target for these common chronic intestinal disorders.

9 Oct 2005

Lab-made version of a human protein opens a new research avenue to better understand rheumatoid arthritis

A lab-made version of a human protein alleviates symptoms of both acute and chronic arthritis in mice and could be the basis for a new arthritis drug for people, report scientists from the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH).

3 Oct 2005